Trial reportAnnals of the American Thoracic Society2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
Trial report in Annals of the American Thoracic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling.Diagnostics (Basel, Switzerland) · 2026Review
- Inhalable Albumin Nanoparticles Co-Delivering Dihydroartemisinin and Nintedanib Attenuate Pulmonary Fibrosis by Suppressing TGF-β1/Smad2/3 Signaling.International journal of nanomedicine · 2026Article
- Multi-omics approaches in idiopathic pulmonary fibrosis: from molecular mechanisms to therapeutic targets and precision medicine.Frontiers in pharmacology · 2026Review
- Inefficacy of dexamethasone and pirfenidone as comparators in the bleomycin-induced pulmonary fibrosis model in SD rats.Frontiers in medicine · 2026Article
- Prevalence, Clinical Features, and Outcomes of Young Patients with Idiopathic Pulmonary Fibrosis.Respiration; international review of thoracic diseases · 2025Article
- Current status of pulmonary rehabilitation and impact on prognosis of patients with idiopathic pulmonary fibrosis in South Korea.Journal of thoracic disease · 2024Article
- Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression.World journal of clinical cases · 2024Article
- Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.Annals of the American Thoracic Society · 2024Article
- Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.Heliyon · 2024Article
- Mast-cell expressed membrane protein-1 is expressed in classical monocytes and alveolar macrophages in idiopathic pulmonary fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ-dependent manner.American journal of physiology. Cell physiology · 2024Article
- Review
- Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.Respirology (Carlton, Vic.) · 2024Article
- Review
- Precision medicine advances in idiopathic pulmonary fibrosis.EBioMedicine · 2023Review
- Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates.BMJ open respiratory research · 2022Observational
- Review
- Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.Respiratory research · 2020Article
- Fibrosis following Acute Skeletal Muscle Injury: Mitigation and Reversal Potential in the Clinic.Journal of sports medicine (Hindawi Publishing Corporation) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 6 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.